Super Carbonate Apatite-miR-497a-5p Complex Is a Promising Therapeutic Option against Inflammatory Bowel Disease
Authors:
- Naoto TsujimuraNTNaoto Tsujimura
- Takayuki OginoTOTakayuki Ogino
- Masayuki HirakiMHMasayuki Hiraki
- Taisei KaiTKTaisei Kai
- Hiroyuki YamamotoHYHiroyuki Yamamoto
- Haruka HiroseHHHaruka Hirose
- Yuhki YokoyamaYYYuhki Yokoyama
- Yuki SekidoYSYuki Sekido
- Tsuyoshi HataTHTsuyoshi Hata
- Norikatsu MiyoshiNMNorikatsu Miyoshi
- Hidekazu TakahashiHTHidekazu Takahashi
- Mamoru UemuraMUMamoru Uemura
Open Access
- 19 April 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (4) , 618
Abstract
The incidence of inflammatory bowel disease (IBD) is increasing worldwide. It is reported that TGF-β/Smad signal pathway is inactivated in patients with Crohn’s disease by overexpression of Smad 7. With expectation of multiple molecular targeting by microRNAs (miRNAs), we currently attempted to identify certain miRNAs that activate TGF-β/Smad signal pathway and aimed to prove in vivo therapeutic efficacy in mouse model. Through Smad binding element (SBE) reporter assays, we focused on miR-497a-5p. This miRNA is common between mouse and human species and enhanced the activity of TGF-β/Smad signal pathway, decreased Smad 7 and/or increased phosphorylated Smad 3 expression in non-tumor cell line HEK293, colorectal cancer cell line HCT116 and mouse macrophage J774a.1 cells. MiR-497a-5p also suppressed the production of inflammatory cytokines TNF-α, IL-12p40, a subunit of IL-23, and IL-6 when J774a.1 cells were stimulated by lipopolysaccharides (LPS). In a long-term therapeutic model for mouse dextran sodium sulfate (DSS)-induced colitis, systemic delivery of miR-497a-5p load on super carbonate apatite (sCA) nanoparticle as a vehicle restored epithelial structure of the colonic mucosa and suppressed bowel inflammation compared with negative control miRNA treatment. Our data suggest that sCA-miR-497a-5p may potentially have a therapeutic ability against IBD although further investigation is essential.Keywords
Funding Information
- Kaken Pharmaceutical (16K15590)
This publication has 82 references indexed in Scilit:
- Treat to Target: A Proposed New Paradigm for the Management of Crohn's DiseaseClinical Gastroenterology and Hepatology, 2015
- Dextran Sulfate Sodium (DSS)‐Induced Colitis in MiceCurrent Protocols in Immunology, 2014
- Increased Th17-Inducing Activity of CD14+ CD163low Myeloid Cells in Intestinal Lamina Propria of Patients With Crohn’s DiseaseGastroenterology, 2013
- Investigating Intestinal Inflammation in DSS-induced Model of IBDJournal of Visualized Experiments, 2012
- Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacyExpert Review of Vaccines, 2011
- Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(d,l-lactide-co-glycolide) nanospheres for inflammatory bowel diseaseBiomaterials, 2011
- Mipomersen as a potential adjunctive therapy for hypercholesterolemiaExpert Opinion on Pharmacotherapy, 2010
- Th17 and Regulatory T Cells in Mediating and Restraining InflammationCell, 2010
- Induction by activated macrophage-like THP-1 cells of apoptotic and necrotic cell death in intestinal epithelial Caco-2 monolayers via tumor necrosis factor-alphaExperimental Cell Research, 2006
- Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel diseaseJournal of Clinical Investigation, 2001